X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Biocon Ltd with Natco Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON vs NATCO PHARMA - Comparison Results

BIOCON     Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON NATCO PHARMA BIOCON /
NATCO PHARMA
 
P/E (TTM) x 40.7 11.4 356.6% View Chart
P/BV x 7.1 3.1 231.9% View Chart
Dividend Yield % 0.2 1.5 11.2%  

Financials

 BIOCON    NATCO PHARMA
EQUITY SHARE DATA
    BIOCON
Mar-18
NATCO PHARMA
Mar-18
BIOCON /
NATCO PHARMA
5-Yr Chart
Click to enlarge
High Rs1,1881,080 110.0%   
Low Rs305671 45.4%   
Sales per share (Unadj.) Rs68.7592.1 11.6%  
Earnings per share (Unadj.) Rs7.6188.4 4.0%  
Cash flow per share (Unadj.) Rs14.0206.3 6.8%  
Dividends per share (Unadj.) Rs1.008.25 12.1%  
Dividend yield (eoy) %0.10.9 14.2%  
Book value per share (Unadj.) Rs86.3833.6 10.4%  
Shares outstanding (eoy) m600.0036.90 1,626.0%   
Bonus/Rights/Conversions ISIS-  
Price / Sales ratio x10.91.5 734.5%   
Avg P/E ratio x98.94.6 2,126.9%  
P/CF ratio (eoy) x53.44.2 1,259.2%  
Price / Book Value ratio x8.61.1 823.0%  
Dividend payout %13.24.4 302.4%   
Avg Mkt Cap Rs m447,90032,311 1,386.2%   
No. of employees `0006.14.8 127.3%   
Total wages/salary Rs m9,3113,256 286.0%   
Avg. sales/employee Rs Th6,705.84,522.5 148.3%   
Avg. wages/employee Rs Th1,514.2674.0 224.7%   
Avg. net profit/employee Rs Th736.91,439.0 51.2%   
INCOME DATA
Net Sales Rs m41,23421,848 188.7%  
Other income Rs m2,062404 510.4%   
Total revenues Rs m43,29622,252 194.6%   
Gross profit Rs m8,2919,284 89.3%  
Depreciation Rs m3,851662 581.7%   
Interest Rs m615154 399.4%   
Profit before tax Rs m5,8878,872 66.4%   
Minority Interest Rs m2130-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,5691,920 81.7%   
Profit after tax Rs m4,5316,952 65.2%  
Gross profit margin %20.142.5 47.3%  
Effective tax rate %26.721.6 123.2%   
Net profit margin %11.031.8 34.5%  
BALANCE SHEET DATA
Current assets Rs m41,48621,307 194.7%   
Current liabilities Rs m21,4135,920 361.7%   
Net working cap to sales %48.770.4 69.1%  
Current ratio x1.93.6 53.8%  
Inventory Days Days6473 87.3%  
Debtors Days Days94107 88.4%  
Net fixed assets Rs m50,66114,986 338.1%   
Share capital Rs m3,000369 813.0%   
"Free" reserves Rs m48,80830,353 160.8%   
Net worth Rs m51,80830,760 168.4%   
Long term debt Rs m17,8980-   
Total assets Rs m99,89737,151 268.9%  
Interest coverage x10.658.6 18.0%   
Debt to equity ratio x0.30-  
Sales to assets ratio x0.40.6 70.2%   
Return on assets %5.219.1 26.9%  
Return on equity %8.722.6 38.7%  
Return on capital %9.629.3 32.8%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m12,05810,322 116.8%   
Fx outflow Rs m7,3482,978 246.7%   
Net fx Rs m4,7107,343 64.1%   
CASH FLOW
From Operations Rs m6,6214,636 142.8%  
From Investments Rs m-6,840-11,155 61.3%  
From Financial Activity Rs m-2,3976,509 -36.8%  
Net Cashflow Rs m-2,612-18 14,511.1%  

Share Holding

Indian Promoters % 40.4 52.0 77.6%  
Foreign collaborators % 20.6 1.5 1,401.4%  
Indian inst/Mut Fund % 8.4 7.8 107.1%  
FIIs % 10.7 16.6 64.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 26.0 76.5%  
Shareholders   109,995 25,395 433.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON With:   PFIZER  GSK PHARMA  PLETHICO PHARMA  WYETH LTD  ABBOTT INDIA  

Compare BIOCON With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 425 Points Higher; Banking and Energy Stocks Witness Buying(Closing)

Indian share markets witnessed buying interest during closing hours and ended their day on a positive note. Gains were largely seen in the banking sector and energy sector.

Related Views on News

NATCO PHARMA Announces Quarterly Results (3QFY19); Net Profit Down 26.7% (Quarterly Result Update)

Feb 14, 2019 | Updated on Feb 14, 2019

For the quarter ended December 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (down 26.7% YoY). Sales on the other hand came in at Rs 6 bn (down 1.0% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

BIOCON LTD Announces Quarterly Results (3QFY19); Net Profit Up 169.2% (Quarterly Result Update)

Jan 28, 2019 | Updated on Jan 28, 2019

For the quarter ended December 2018, BIOCON LTD has posted a net profit of Rs 2 bn (up 169.2% YoY). Sales on the other hand came in at Rs 15 bn (up 45.6% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

NATCO PHARMA Announces Quarterly Results (2QFY19); Net Profit Up 115.2% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (up 115.2% YoY). Sales on the other hand came in at Rs 5 bn (up 27.4% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

BIOCON LTD Announces Quarterly Results (2QFY19); Net Profit Up 501.9% (Quarterly Result Update)

Nov 9, 2018 | Updated on Nov 9, 2018

For the quarter ended September 2018, BIOCON LTD has posted a net profit of Rs 4 bn (up 501.9% YoY). Sales on the other hand came in at Rs 13 bn (up 36.4% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

NATCO PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 93.3% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (up 93.3% YoY). Sales on the other hand came in at Rs 5 bn (up 21.0% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

More Views on News

Most Popular

My Top 3 Defence Stocks to Buy Now(The 5 Minute Wrapup)

Mar 19, 2019

The urgency to privatise India's defence sector to make India self-reliant was never as strong as it is today.

This Small Cap Stock Could Offer Triple Digit Gains from its Current Price(Profit Hunter)

Mar 19, 2019

If you are still waiting for signals, remember, there is no correct timing, only right time to Buy stocks. For select small caps, that time is now.

5 Fundamentally Strong Stocks to Pick for Trading Today(Profit Hunter)

Mar 15, 2019

5 fundamentally strong stocks one could buy to trade in this market right now. Make sure you grab the chance this strongly rallying market offers.

Elections Don't Matter!(The Honest Truth)

Mar 13, 2019

Ajit Dayal shows us why from the point of view of the Indian economy, elections don't matter.

Two Growth Stocks that Doubled in a Little Over 12 Months!(The 5 Minute Wrapup)

Mar 13, 2019

The elements that fueled profit growth for these two companies led to a surge in their stock prices.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON SHARE PRICE


Mar 26, 2019 03:35 PM

TRACK BIOCON

COMPARE BIOCON WITH

MARKET STATS